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Abstract
Dominant paradigms for the understanding of rheumatoid arthritis (RA) pathogenesis have
changed over the years. A predominant role of B lymphocytes, and perhaps of the
rheumatoid factor they produced, was initially invoked. In more recent years, recognition of
antigens in the joint by T cells sparking an inflammatory cascade has been a more favored
interpretation. Here, we re-examine some of the arguments that underpin this proposed role
of joint T cells, in light of recent results from transgenic mice in which a self-reactive T-cell
receptor provokes disease, but from outside the joint and indirectly via B lymphocytes and
immunoglobulins.
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CIA = collagen-induced arthritis; GPI = glucose-6-phosphate isomerase; MHC = major histocompatibility complex; RA = rheumatoid arthritis;
RF = rheumatoid factor; TCR = T-cell receptor.
http://arthritis-research.com/content/2/2/090
Introduction
Favoured explanations for the pathogenesis of RA have
changed several times over the past four decades, and
our understanding of this mysterious disease remains neb-
ulous. Today, few dispute that the effector phase involves
angiogenesis, chemotaxis and activation of monocytic
cells, anarchic proliferation of synoviocytes, and the
release of a witch’s brew of inflammatory cytokines, pro-
teases and glycolytic enzymes, which ultimately results in
cartilage and bone destruction. The tantalizing unan-
swered questions relate to the upstream steps that initiate
this process; we have many clues, but little definitive infor-
mation.
Development of autoimmune paradigms in
rheumatoid arthritis
The role of immunological perturbations in starting the
arthritis process seems reasonably established, but there
have been several changes in the reigning paradigm to
explain how autoimmune deviation provokes inflammation
and destruction of the joint. In the 1960s, a series of
immunochemical findings placed RA in the realm of B lym-
phocyte disorders, via their immunoglobulin products.
These findings include the following: the frequent detec-
tion of autoantibodies, in particular of rheumatoid factor
(RF; anti-immunoglobulin G); the presence of immune
complexes and of reduced complement levels in the joint;
and the observation of immunoglobulin deposits and of
intracytoplasmic inclusions, composed of immunoglobu-
lins and complement, in phagocytes. These findings sug-
gested a paradigm according to which local immune
responses, taking place in the joint and directed against
joint components, produce arthritogenic autoantibodies
[1]. These immunoglobulins would then complex with their
specific antigen, activating resident phagocytic cells of the
synovial lining, and starting the complement cascade.
Soluble mediators produced as a result would attract
more monocytic cells and stimulate anarchic proliferationhttp://arthritis-research.com/content/2/2/090
of synoviocytes. The presence in RA synovium of plasma
cells and B lymphocytes organized in follicle-like forma-
tions gave a cellular footing to this idea. Some investiga-
tors (eg Ohno and Cooke [2]) argued for a related
paradigm by which a microbe-initiated systemic B-cell
response resulted in an immune complex disease.
During the ensuing 20 years, however, these notions
changed, with B cells losing precedence to T cells as the
principal agents provocateurs in RA. The relevance of RF
to RA pathogenesis became rather suspect, because RF
is absent in a substantial proportion of RA patients and,
conversely, high-affinity somatically mutated RF was found
in many other instances of chronic immune stimulation [3].
Other autoantibodies were even more inconstant. Further-
more, no evidence for directly pathogenic antibodies in RA
patients was obtained [4,5]. Several arguments [6–8]
gave credence to an alternative paradigm that is centred
on T cells; synovitis was no longer thought to be induced
by antibodies, but rather by a cell-mediated process akin
to delayed-type hypersensitivity, involving the local activa-
tion of T cells by antigen-presenting cells. This stimulation
released inflammatory cytokines, which activated synovio-
cytes and monocytes, initiating the monocyte-mediated
destructive process described above. Although there was
some debate as to the relative roles of T and inflammatory
cells once the disease had started [6,9], these views all
postulated that joint autoantigen recognition by T cells,
and not by antibodies, was at the root of RA (Fig. 1a).
The T cell perturbation in these models was proposed to
correspond to responses to joint-specific antigens, which
could occur for one of several reasons: aberrant selection
of an autoimmune repertoire in the thymus; unmasking of
cryptic self-epitopes or epitope spreading after a local
response to a microbe; or molecular mimicry after a
distant infection. In some variants, it was proposed that
primary alterations in joint antigen-presenting cells led to
presentation of neo-antigens to T cells [10]. The following
were the arguments proposed in support of such models:
(1) The linkage that was discovered between RA and par-
ticular major histocompatibility complex (MHC) class II
haplotypes [11], with sequence motifs shared between
DRb alleles linked to susceptibility [12]. As the main
function of MHC class II molecules is to present pep-
tides to T cells, this implied a determining role for the
presentation of particular peptides.
(2) The importance of T cells in animal models of RA, such
as collagen-induced arthritis (CIA), T-cell populations
or clones being able to provoke disease in normal
mice.
(3) The presence of T lymphocytes in synovial tissue and
fluid.
(4) The activated/memory phenotype of these T cells, sug-
gesting that they are involved in a local immune
response [6].
(5) Reports of oligoclonal expansion of these infiltrating
T cells [13,14], implying reactivity to a restricted set of
antigenic peptides or to a superantigen.
(6) The beneficial effect of therapies that target T cells,
such as treatment with anti-CD4 monoclonal antibod-
ies [15].
Figure 1
Models of T cell invovement in rheumatoid arthritis (RA). (a) The
‘classical’ model. T cells within the joint recognize fragments of
autoantigens presented by local dendritic cells (DCs). As a
consequence they produce inflammatory cytokines that directly affect
chondrocytes, but mainly prime monocytes and synoviocytes (either
fibroblastic or macrophage-like) to produce more substantial amounts of
monokines (eg tumor necrosis factor), proteases or glycosidases to
effect cartilage destruction and bone remodeling. In this view, there may
be local activation of B cells to produce immunoglobulins directed
against joint-specific structures, but this is an ancillary pathway. (b) In
this model, T-cell activation occurs outside the joint, and is not
necessarily caused by joint-specific peptides. The relevant mode of
antigen presentation is by B cells, which have picked up rare antigen
molecules via their surface immunoglobulin, and are thus preferentially
helped. The arthritogenic immunoglobulin they produce (in isolation or
in complexed form) then diffuses to the joint. In this locale,
immunoglobulin binding or activation by immune complexes provokes
the release of chemokines, attracting and priming monocytes to elicit
cartilage and joint destruction (and secondary release of B and T cells).Arthritis Research    Vol 2 No 2 Benoist and Mathis
This ‘T-cell centric’ paradigm was conceptually similar to
the favored interpretations of other T-cell-mediated
autoimmune diseases, such as type I (insulin dependent)
diabetes mellitus, in which autoantigen recognition by
T cells appears to be the primary trigger of tissue destruc-
tion. It led to proposals of therapeutic strategies designed
to block T-cell receptors (TCRs) that are reactive to joint
antigens [16]. Issues remaining at the forefront were to
identify the joint-specific T cell antigens in order to pin-
point the TCR V regions used in their recognition, why
these autoantigens are uniquely recognized in diseased
individuals, and to understand the adhesive interactions
that concentrate T cells in the joint.
K/BxN transgenic mouse model
We have recently described a transgenic mouse model of
inflammatory arthritis that is quite reminiscent of RA
[17,18]. Even though this model has T-cell autoreactivity
at its root, the pathogenic process follows a conceptually
different path to that described above. Thus, it might be
interesting to re-evaluate the interpretations of RA patho-
genesis in this light.
The K/BxN model [17,18] has been reviewed in detail
elsewhere [19,20], and it is not our intent to describe it at
length here. Briefly, disease is provoked by a self-reactive
TCR that is encoded by cointegrated TCR-a and TCR-b
transgenes. This TCR recognizes a peptide that is derived
from a ubiquitous self-antigen [glucose-6-phosphate iso-
merase (GPI) [21], and provokes the differentiation and
proliferation of B cells with surface immunoglobulin that
reacts against the same molecule. The autoantibodies, in
turn, are directly pathogenic upon transfer, inducing arthri-
tis even in the complete absence of any lymphocytes in
the joint. The synovitis induced by the arthritogenic anti-
bodies involves the initiation of an inflammatory process
via complement and Fcg receptor pathways (Ji H, unpub-
lished data). The pathogenic cascade operating in these
mice is shown in Figure 1b. A few points that differentiate
it from most previous models of RA should be stressed:
reactivity is against a ubiquitous autoantigen, that has no
known joint specificity; and T cells initiate disease by
coaxing B cells to produce pathogenic immunglobulins,
but this takes place outside the joint.
Applicability of the K/BxN pathogenic pathway
to rheumatoid arthritis?
The disease in K/BxN mice does differ somewhat from
that in RA patients (eg in the precise distribution of the
joints involved, the degree of aggressiveness and the
extent of remodeling that follows destruction). One should
bear in mind, however, that few humans are likely to have
the skewed repertoire of a TCR transgenic mouse, and
that mouse and human locomotor physiologies are differ-
ent. It seems of less value to debate the significance of
distal interphalangial joint inflammation or whether tail
inflammation in mice has a correlate in humans than to ask
whether the mechanism that operates in the transgenic
animals might also, in a generic manner, underlie disease
in humans.
Let us, then, reconsider the above-listed arguments in
support of the notion that T cells that recognize antigens
in the joint drive effector functions in RA.
(1) The linkage to certain MHC II alleles. This is clearly a
strong argument for T-cell involvement, but such a
linkage is equally compatible with MHC class II-
restricted responses by CD4+ cells that occur outside
the joint, as in K/BxN mice. It may be worth stressing
that arthritis in the transgenic animals exhibits a strin-
gent requirement for a particular MHC class II mole-
cule to guide T–B cell collaboration [17].
(2) The role of T cells in CIA. The disease that is induced
in rodents immunized with articular collagen can
indeed be transferred to normal animals by T-cell pop-
ulations or clones derived from responding mice (as
from K/BxN mice). However, there is no compelling
evidence that transferred T cells need act locally,
rather than by stimulating the production of autoanti-
bodies in draining lymph nodes, as normally occurs
when T cells help B cells. Indeed, it has been demon-
strated that serum and monoclonal antibodies from
mice with CIA can also induce disease in normal recip-
ients, but not always very efficiently [22].
(3) The presence of T cells in RA synovial fluid and tissue.
This might have been the most misleading clue; does
presence necessarily imply function? Nothing indicates
that T cells in RA joints, with representation that varies
widely between individuals, are not mere bystanders
attracted by the chemokines and the changes in adhe-
sive properties of the vascular endothelium generated
by an intense inflammatory process.
(4) The activated phenotype of joint-infiltrating T cells.
Again, this is guilt by innuendo. It seems hardly likely
that T lymphocytes would remain impassive in the
‘swirling maelstrom of inflammatory cytokines’ [6] of an
arthritic joint. Furthermore, it is known that activated
T cells are more efficient than naïve cells in their ability
to migrate to nonlymphoid tissues; the activated status
of T cells in RA joints might just reflect preferential
recruitment also.
(5) The early reports of oligoclonal expansion of T cells in
joints have not proved to be repeatable or generalize-
able. Technical artifacts linked to small sample sizes
(‘founder effects’ in reverse transcription polymerase
chain reaction) have probably been a major factor in
these contradictory data [8].(6) Similarly, early suggestions of a high efficacy of anti-
CD4 treatments have not been supported in the long
run [23,24]. Interestingly, anti-CD4 therapy is only
effective when administered before pathogenic anti-
body accumulates and inflammation begins in the
K/BxN mice [17]; might one need to treat RA patients
pre-emptively, which is not really a viable strategy.
In short, some of the arguments that pointed to a patho-
genic role for joint T cells are certainly open to question;
others are equally applicable to a ‘remote’ mode of T cell
implication, as in K/BxN mice. Such a scenario might also
explain more readily the extra-articular manifestations of
many RA patients; circulating autoantibodies that induce
joint inflammation could conceivably cause lesions in con-
nective tissue of the heart and lung as well.
To a large extent, the mode of pathogenesis that emerges
in the K/BxN model brings us back to the dominant ‘B-cell
centric’ paradigms of the 1960s and 1970s. There are
two important nuances, though. First is the locale of
autoantibody production. The pathogenic B cells were
often thought to be localized in the joint, which is consis-
tent with the presence of activated B cells and plasma
cells in RA synovium, leading to many attempts to identify
dominant idiotypes or antigenic targets of immunoglobulin
produced in the synovium [25]. The ‘presence does not
automatically imply function’ caveat evoked above also
applies here, however, and these B lineage cells may just
as well be innocent bystanders or partake in secondary
responses, as they are in the insulitic lesions of autoim-
mune diabetes. That arthritis can be induced by anti-GPI
antibodies opens the door to alternative explanations that
are not based on immunoglobulin responses generated in
the joint, or even directed against joint-specific antigens.
As often pointed out by others [1,15], the blood–tissue
barrier in the joint has a unique disposition, marked in par-
ticular by the absence of a basal membrane. This may help
explain why responses to a ubiquitous antigen can have
joint-specific consequences. The second nuance is that
T cells do play a primary role in the pathogenesis of the
K/BxN disease, which, after all, does stem from the
expression of a TCR transgene. Of course, pathogenic
B cells are known to require some help from T cells, but it
was not as clear that primary autoreactivity in the T-cell
compartment would be sufficient to jump-start the
process, by recruiting B cells with surface immunoglobulin
receptors directed against the same molecule.
Conclusion
In the end, is the mode of arthritis pathogenesis in K/BxN
mice applicable in RA patients, or more particularly to one
of its forms? (The polymorphism of the disease as
presently diagnosed does allow room for several modes of
pathogenesis). Certainly, there is a burden of proof to iden-
tify pathogenic antibodies in serum from RA patients, and
to test whether any of the known autoreactivities in RA
patients [25] might have a pathogenic role similar to that of
anti-GPI in mice. Certainly, no direct evidence has been
reported for pathogenic immunoglobulins in RA [4,5], but
one can easily imagine why they may have been technically
difficult to identify. It will also be important to solve the
riddle of how and why antibodies to a ubiquitously
expressed protein can provoke joint-specific disease. Until
then, the main value of the K/BxN model may be to ques-
tion some of the assumptions of the paradigms that
presently dominate our view of RA. We should perhaps
look for pathogenic B and T cells outside the confines of
the joint and joint-specific antigens. One may also wish to
consider therapeutic approaches aimed at T cells more
prudently; if they are indeed helping pathogenic B cells,
and in particular if the isotopes of the antibodies they sepa-
rate have disease significance, attempts to tinker with T-
helper 1/T-helper 2 balance might prove most deleterious.
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